Instrucciones de búsqueda:
* Filter the ENTIRE resource library: Choose a OR a to sort all resources.
* Choose Search Items : to filter one collection or perform complex queries.
* Choose Browse by Topic to search by one or more Topics.
Navegar por los elementos (92 total)
-
Autor: NETEC
Tema: Treatment & Care
Tipo de elemento: Video
Fecha de actualización: 2022-09-09
Descripción: In this video, we demonstrate the technique of intradermal medication administration. In the 2022 monkeypox outbreak, this technique is being used to administer the Jynneos smallpox and monkeypox vaccine in order to increase the number of available… -
Autor: CDC
Tema: Treatment & Care
Tipo de elemento: Guía
Fecha de actualización: 2022-08-23
Descripción: VACCINE INFORMATION STATEMENT -
Autor: FDA
Tema: Treatment & Care
Tipo de elemento: Guía
Fecha de actualización: 2022-04
Descripción: JYNNEOS is a vaccine indicated for prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection.Includes: indications and usage, dosage and administration, dosage… -
Autor: World Health Organization
Tema: General
Tipo de elemento: Guía
Fecha de actualización: 2022
Descripción: Worldwide, the number of potential pathogens is very large, while the resources for disease research and development (R&D) is limited. To ensure efforts under WHO’s R&D Blueprint are focused and productive, a list of diseases and pathogens are… -
Autor: Bar-On, Yinon M., Yair Goldberg, Micha Mandel, Omri Bodenheimer, Laurence Freedman, Nir Kalkstein, Barak Mizrahi, Sharon Alroy-Preis, Nachman Ash, Ron Milo, and Amit Huppert.
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2021-10-07
Descripción: On July 30, 2021, the administration of a third (booster) dose of the BNT162b2 messenger RNA vaccine (Pfizer–BioNTech) was approved in Israel for persons who were 60 years of age or older and who had received a second dose of vaccine at least 5… -
Autor: Li, L., L. B. Robinson, R. Patel, A. B. Landman, X. Fu, E. S. Shenoy, D. M. Hashimoto, A. Banerji, P. G. Wickner, U. Samarakoon, C. M. Mancini, Y. Zhang, and K. G. Blumenthal.
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2021-10-01
Descripción: Allergic history in individuals with confirmed anaphylaxis to a messenger RNA (mRNA) COVID-19 vaccine is common. However, the risk factors for allergy symptoms after receiving the vaccine are unknown. -
Autor: Xia, ShengLi, YunTao Zhang, YanXia Wang, Hui Wang, YunKai Yang, George Fu Gao, WenJie Tan, GuiZhen Wu, Miao Xu, ZhiYong Lou, WeiJin Huang, WenBo Xu, BaoYing Huang, Wei Wang, Wei Zhang, Na Li, ZhiQiang Xie, Xiujuan Zhu, Ling Ding, WangYang You, YuXiu…
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2021-09-15
Descripción: Although SARS-CoV-2 infection often causes milder symptoms in children and adolescents, young people might still play a key part in SARS-CoV-2 transmission. An efficacious vaccine for children and adolescents could therefore assist pandemic control.… -
Autor: Barda, Noam, Noa Dagan, Yatir Ben-Shlomo, Eldad Kepten, Jacob Waxman, Reut Ohana, Miguel A. Hernán, Marc Lipsitch, Isaac Kohane, Doron Netzer, Ben Y. Reis, and Ran D. Balicer.
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2021-08-25
Descripción: Preapproval trials showed that messenger RNA (mRNA)–based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a good safety profile, yet these trials were subject to size and patient-mix limitations. An evaluation of the… -
Autor: The Medical Letter on Drugs and Therapeutics
Tema: Treatment & Care
Tipo de elemento: Publicación
Fecha de actualización: 2021-07-15
Descripción: COVID-19 Vaccine Comparison Chart (online only) effectiveness by vaccine and by variant. -
Autor: Kamar, Nassim, Florence Abravanel, Olivier Marion, Chloé Couat, Jacques Izopet, and Arnaud Del Bello.
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2021-06-23
Descripción: A weak immune response to two doses of vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been observed in recipients of solid-organ transplants.